This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Osiris, Arena, Ampio

Based on this lukewarm recommendation, Canadian regulators approved Prochymal on May 17 with conditions that restricts use of the stem cell therapy and requires Osiris to provide further clinical data to prove its clinical benefit.

This is not the ringing endorsement of Prochymal that Osiris has portrayed since the Canadian approval was announced last month. A read of the Prochymal label approved in Canada makes that point clear.

"Protocol 280" was a double-blind, placebo-controlled phase III study that enrolled 240 patients with steroid-refractory GVHD. In 2009, Osiris announced that the "protocol 280" study failed, as did a companion phase III study in newly diagnosed GVHD patients. Prochymal provided little or no benefit over placebo.

Osiris, however, sifted through the negative phase III study to find a subgroup of 28 children with all grades of GVHD --14 treated with Prochymal and 14 with a placebo. In this retrospectively defined subgroup, the Prochymal response rate at day 28 was 64% versus 36% for the placebo-treated patients -- a trend favoring Prochymal but not statistically significant.

The survival data from this data-mined subgroup of children is equally weak. At day 100, 11 Prochymal patients (78.6%) were alive compared to seven placebo-treated patients (50%). The result was not statistically significant.

At day 180, the survival "benefit" narrows, with nine Prochymal-treated kids alive versus seven placebo-treated kids.

Health Canada also considered data from "Protocol 275," a single-arm (uncontrolled) study of 75 pediatric patients with Grades B-D acute GVHD who failed to respond to other treatments. [GVHD severity is graded A-D, with A least severe, D most severe.]

At day 28, the patient response to Prochymal was 61%, but unlike in protocol 180, there was no control arm to which the Prochymal response could be compared.

In order to examine survival in protocol 275, Osiris compared Prochymal to a historical control of "similar" GVHD patients. The probability of survival at 180 days post treatment was 51% for Grade D GVHD patients treated with Prochymal compared to 31% for the historical control group -- statistically significant.

But the same survival analysis conducted for patients with milder Grades B&C GVHD failed to demonstrate favoring Prochymal. In fact, survival trended in favor of the historical control for Grade C GVHD patients.
3 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AMPE $2.37 0.00%
ARNA $4.44 0.00%
OSIR $19.27 0.00%
VVUS $2.31 0.00%
AAPL $126.44 0.00%

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs